Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Eisai Posts Flat Revenue in Q1, Lenvima Sales Double
Eisai’s first-quarter sales were virtually flat, barely remaining in positive territory with a 0.5% rise as continued growth of its major cancer drug Lenvima (lenvatinib) more than cancelled out one-off negatives, according to its earnings released on July 31. In…
To read the full story
Related Article
- Eisai Chalks Up Record Profits on Lenvima Boon
May 14, 2020
- Eisai's April-December Operating Profit Surges 28.4% on Lenvima, Guidance Lifted
February 3, 2020
- Eisai Sees Brisk Sales of Global Brands, but Earnings Slump on One-Off Factors
October 31, 2019
- Eisai’s FY2018 Net Profit Jumps 22.3% on Merck Deal, Global Brands
May 14, 2019
BUSINESS
- Kissei Urges Halt to New Tavneos Use after Fatal Liver Injury Reports
May 18, 2026
- Eisai Hits Record Sales as Leqembi Revenue Nearly Doubles in FY2025
May 18, 2026
- Kaken Files Vascular Malformation Drug in Japan, Eyes FY2027 Approval
May 18, 2026
- Regenxbio Appeals FDA CRL for MPS II Gene Therapy RGX-121
May 18, 2026
- Fuji Sees New Bio-AG Pricing Rules as Tailwind for Biosimilars
May 18, 2026
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…